Could the coronavirus lead to a reassessment of vaccine patent laws?

Coronavirus vaccine development.
(Image credit: Getty Images)

Adar Poonawalla, the CEO of India's Serum Institute, is working to mass-produce a low-cost coronavirus vaccine for the entire world, but the pharmaceutical industry and intellectual property laws remain hurdles, Politico reports.

Poonawalla is hoping the urgency of the pandemic leads to a reassessment of patent laws, which he says limit access to immunizations in developing countries while driving up prices in wealthier ones. "If you don't allow, for example, an Indian producer to sell in the U.S. because of some stupid rules and regulations, even though the product is identical to the U.S. product, you're going to have a supply situation," he told Politico. "And guess what. When you've got a low supply and high demand, what happens to the price? It skyrockets."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.